Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: A double-blind randomized study

Journal of Affective Disorders

Volumn 143, Issue 1-3, 2012, Pages 47-55

  Romera, Irene ^a,b   Pérez, Victor ^c   Manuel Menchón, Jose ^d   Schacht, Alexander ^e   Papen, Rita ^e   Neuhauser, Doris ^f   Abbar, Mocrane ^g   Picard, Hernan ^h   Gilaberte, Inmaculada ⁱ  

^a DAEDALUS Data Decisions and Language SA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f ELI LILLY AND COMPANY   (United States)

^g DEPARTMENT OF NEUROLOGY   (France)

^h CENTRE HOSPITALIER SAINTE ANNE   (France)

ⁱ ELI LILLY AND COMPANY   (Spain)

Author keywords

Antidepressant switch; Early switch strategy; Major depressive disorder; Painful physical symptoms; Treatment optimization

Indexed keywords

DULOXETINE; ESCITALOPRAM;

ADULT; ARTICLE; BACKACHE; COMPARATIVE STUDY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; RHINOPHARYNGITIS; SHEEHAN DISABILITY SCALE; SHOULDER PAIN; SIDE EFFECT; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WAKEFULNESS; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84869491329     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2012.05.024     Document Type: Article

References (41)

1. American Psychiatric Association, 1994, Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third ed. Available at 〈http://www.psychiatryonline.com/pracGuide/pracGuideChapToc-7.aspx〉.
2. I.M. Anderson, D.J. Nutt, and J.F. Deakin Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British association for psychopharmacology Journal of Psychopharmacology 14 2000 3 20
3. J. Axford, C. Heron, F. Ross, and C.R. Victor Management of knee osteoarthritis in primary care: pain and depression are the major obstacles Journal of Psychosomatic Research 64 2008 461 467
4. M.J. Bair, R.L. Robinson, G.J. Eckert, P.E. Stang, T.W. Croghan, and K. Kroenke Impact of pain on depression treatment response in primary care Psychosomatic Medicine 66 2004 17 22
5. M.J. Bair, R.L. Robinson, W. Katon, and K. Kroenke Depression and pain comorbidity: a literature review Archives of Internal Medicine 163 2003 2433 2445
6. M.J. Detke, Y. Lu, D.J. Goldstein, J.R. Hayes., and M.A. Demitrack Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial Journal of Clinical Psychiatry 63 2002 308 315
7. M. Fava Switching treatments for complicated depression Journal of Clinical Psychiatry 71 2 2010 e04
8. M. Fava, G.I. Papakostas, T. Petersen, Y. Mahal, F. Quitkin, J. Stewart, and P. McGrath Switching to bupropion in fluoxetine-resistant major depressive disorder Annals of Clinical Psychiatry 15 2003 17 22
9. M. Fava, C.H. Mallinckrodt, M.J. Detke, J.G. Watkin, and M.M. Wohlreich The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? Journal of Clinical Psychiatry 65 2004 521 530
10. L.J. Fochtmann, and A.J. Gelenberg Guideline Watch: Practice guideline for the treatment of patients with major depressive disorder 2 2005 American Psychiatric Association Washington, DC
11. M.J. Gameroff, and M. Olfson Major depressive disorder, somatic pain, and health care costs in an urban primary care practice Journal of Clinical Psychiatry 67 2006 1232 1239
12. T.L. Greer, B.T. Kurian, and M.H. Trivedi Defining and measuring functional recovery from depression CNS Drugs 24 2010 267 284
13. M. Hamilton A rating scale for depression Journal of Neurology, Neurosurgery, and Psychiatry 23 1960 56 62
14. M. Hamilton Development of a rating scale for primary depressive illness. Br Journal of Social and Clinical Psychology 6 1967 278 296
15. R.M. Hirschfeld The use of mirtazapine in difficult-to-treat patient populations Human Psychopharmacology 17 Suppl 1 2002 S33 S36
16. R.M. Hirschfeld, C. Mallinckrodt, T.C. Lee, and M.J. Detke Time course of depression-symptom improvement during treatment with duloxetine Depression and Anxiety 21 2005 170 177
17. M.B. Keller Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond Journal of the American Medical Association 18 2003 3152 3160
18. K. Kroenke, J. Shen, T.E. Oxman, J.W. Williams Jr., and A.J. Dietrich Impact of pain on the outcomes of depression treatment: results from the RESPECT trial Pain 134 2008 209 215
19. A.F. Leuchter, M.M. Husain, I.A. Cook, M.H. Trivedi, S.R. Wisniewski, W.S. Gilmer, J.F. Luther, M. Fava, and A.J. Rush Painful physical symptoms and treatment outcome in major depressive disorder: a STARD (Sequenced Treatment Alternatives to Relieve Depression) report Psychological Medicine 40 2010 239 251
20. M.P. Lunn, R.A. Hughes, and P.J. Wiffen Duloxetine for treating painful neuropathy or chronic pain Cochrane Database of Systematic Reviews 2009 Oct 7:CD007115
21. S. Nakajima, H. Uchida, T. Suzuki, K. Watanabe, J. Hirano, T. Yagihashi, H. Takeuchi, T. Abe, H. Kashima, and M. Mimura Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression: a randomized open-label trial Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 2011 1983 1989
22. National Institute of Healthy and Clinical Excellence (NICE), 2010, The Treatment and Management of Depression in Adults, in The British Psychological Society & The Royal College of Psychiatrists. Available from: 〈http://www.nice.org.uk/nicemedia/live/12329/45896/45896.pdf〉.
23. A.A. Nierenberg, N.E. McLean, J.E. Alpert, J.J. Worthington, J.F. Rosenbaum, and M. Fava Early nonresponse to fluoxetine as a predictor of poor 8-week outcome American Journal of Psychiatry 152 1995 1500 1503
24. A.A. Nierenberg, A.H. Farabaugh, J.E. Alpert, J. Gordon, J.J. Worthington, J.F. Rosenbaum, and M. Fava Timing of onset of antidepressant response with fluoxetine treatment American Journal of Psychiatry 157 2000 1423 1428
25. A.A. Nierenberg, G.I. Papakostas, T. Petersen, K.E. Kelly, B.M. Iacoviello, J.J. Worthington, J. Tedlow, J.E. Alpert, and M. Fava Nortriptyline for treatment-resistant depression Journal of Clinical Psychiatry. 64 2003 35 39
26. G.I. Papakostas, M. Fava, and M.E. Thase Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches Biological Psychiatry 637 2008 699 704
27. D.G. Perahia, D. Quail, D. Desaiah, E. Corruble, and M. Fava Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques Journal of Clinical Psychiatry. 69 2008 95 105
28. D.G. Perahia, D. Quail, D. Desaiah, A.L. Montejo, and A.F. Schatzberg Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression Journal of Psychiatric Research 43 2009 512 518
29. F.M. Quitkin, P.J. McGrath, J.W. Stewart, K. Ocepek-Welikson, B.P. Taylor, E. Nunes, D. Deliyannides, V. Agosti, S.J. Donovan, E. Petkova, and D.F. Klein Chronological Milestones to Guide Drug Change: When Should Clinicians Switch Antidepressants? Archives of General Psychiatry 53 1996 785 792
30. I. Romera, V. Pérez, J.M. Menchón, A. Schacht, R. Papen, D. Neuhauser, M. Abbar, P. Svanborg, and I. Gilaberte Early switch strategy in patients with major depressive disorder: a double-blind randomized study Journal of Clinical Psychiatry. 2012 2012
31. A.J. Rush, M.H. Trivedi, S.R. Wisniewski, J.W. Stewart, A.A. Nierenberg, M.E. Thase, L. Ritz, M.M. Biggs, D. Warden, J.F. Luther, K. Shores-Wilson, G. Niederehe, and M. Fava STARD Study Team Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression New England Journal of Medicine 354 2006 1231 1242
32. D. Sagman, D. McIntosh, M.S. Lee, H. Li, S. Ruschel, N. Hussain, R.E. Granger, A.C. Lee, and J. Raskin Attributes of response in depressed patients switched to treatment with duloxetine International Journal of Clinical Practice 65 2011 73 81
33. D.V. Sheehan The Anxiety Disease 1983 Charles Scribneŕs Sons New York, NY
34. K.H. Sheehan, and D.V. Sheehan Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale International Clinical Psychopharmacology 23 2008 70 83
35. D.V. Sheehan, P.R. Chokka, R.E. Granger, R.J. Walton, J. Raskin, and D. Sagman Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine Human Psychopharmacology 2011 10.1002/hup.1199
36. G.E. Simon, M. von Korff, M. Piccinelli, C. Fullerton, and J. Ormel An international study of the relation between somatic symptoms and depression New England Journal of Medicine 341 1999 1328 1335
37. A. Szegedi, M.J. Müller, I. Anghelescu, C. Klawe, R. Kohnen, and O. Benkert Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression Journal of Clinical Psychiatry. 64 2003 413 420
38. A. Szegedi, W.T. Jansen, A.P. van Willigenburg, E. van der Meulen, H.H. Stassen, and M.E. Thase Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients Journal of Clinical Psychiatry. 70 2009 344 353
39. M.E. Thase, E.S. Friedman, and R.H. Howland Venlafaxine and treatment-resistant depression Depression and Anxiety 12 Suppl 1 2000 55 62
40. M.H. Trivedi, M. Fava, S.R. Wisniewski, M.E. Thase, F. Quitkin, D. Warden, L. Ritz, A.A. Nierenberg, B.D. Lebowitz, M.M. Biggs, J.F. Luther, K. Shores-Wilson, and A.J. Rush STARD Study Team medication augmentation after the failure of SSRIs for depression New England Journal of Medicine. 354 2006 1243 1252
41. M. Zimmerman, M.A. Posternak, J. McGlinchey, M. Friedman, N. Attiullah, and D. Boerescu Validity of a self-report depression symptom scale for identifying remission in depressed outpatients Comprehensive Psychiatry 47 2006 185 188